Option Care Health's (OPCH) Outperform Rating Reaffirmed at Barrington Research

Option Care Health (NASDAQ:OPCH - Get Free Report)'s stock had its "outperform" rating reissued by research analysts at Barrington Research in a report released on Monday,Benzinga reports. They currently have a $38.00 target price on the stock. Barrington Research's price target points to a potential upside of 15.50% from the stock's current price.

A number of other equities analysts have also weighed in on OPCH. JPMorgan Chase & Co. boosted their price target on shares of Option Care Health from $40.00 to $41.00 and gave the stock an "overweight" rating in a research report on Thursday, March 6th. Jefferies Financial Group upgraded Option Care Health from a "hold" rating to a "buy" rating and boosted their target price for the stock from $26.00 to $35.00 in a report on Thursday, January 23rd. JMP Securities reaffirmed a "market outperform" rating and issued a $30.00 price target (down previously from $31.00) on shares of Option Care Health in a report on Friday, January 10th. Finally, Bank of America raised Option Care Health from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $26.00 to $33.00 in a research note on Monday, January 13th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $33.75.

Option Care Health Price Performance

OPCH stock traded up $0.72 during midday trading on Monday, reaching $32.90. The stock had a trading volume of 1,560,649 shares, compared to its average volume of 1,776,791. Option Care Health has a 52-week low of $21.39 and a 52-week high of $35.53. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77. The company's fifty day simple moving average is $33.36 and its 200 day simple moving average is $28.76. The company has a market cap of $5.40 billion, a price-to-earnings ratio of 27.65, a price-to-earnings-growth ratio of 2.30 and a beta of 1.07.

Insiders Place Their Bets

In related news, insider Michael Bavaro sold 30,996 shares of Option Care Health stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $33.26, for a total value of $1,030,926.96. Following the completion of the sale, the insider now owns 44,974 shares in the company, valued at approximately $1,495,835.24. This trade represents a 40.80 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.64% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Option Care Health

A number of institutional investors have recently modified their holdings of OPCH. Wellington Management Group LLP grew its position in Option Care Health by 84.6% in the 4th quarter. Wellington Management Group LLP now owns 18,325,123 shares of the company's stock valued at $425,143,000 after acquiring an additional 8,400,208 shares in the last quarter. Norges Bank acquired a new position in shares of Option Care Health in the fourth quarter worth $60,219,000. Allspring Global Investments Holdings LLC raised its stake in shares of Option Care Health by 6,525,926.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 1,500,986 shares of the company's stock valued at $52,459,000 after acquiring an additional 1,500,963 shares in the last quarter. Voloridge Investment Management LLC purchased a new position in Option Care Health in the fourth quarter valued at $27,428,000. Finally, Freestone Grove Partners LP purchased a new position in Option Care Health in the fourth quarter valued at $17,487,000. 98.05% of the stock is owned by institutional investors and hedge funds.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.